Drug intelligence / Profile preview

Drusen Laz

Development stage: Unknown
Lead developer: SIFI
Modality: Small Molecules
Administration: Oral

Overview

Drusen Laz is an investigational oral antioxidant combination therapy developed by the University of Guadalajara. It is specifically formulated to mitigate oxidative stress and improve mitochondrial function in patients with proliferative diabetic retinopathy. The formulation contains a blend of carotenoids (lutein, astaxanthin, zeaxanthin), vitamins (C and E), and minerals (zinc and copper). It is currently being evaluated in Phase 2 clinical trials to assess its impact on oxidative stress markers in the aqueous and vitreous humor of patients undergoing vitrectomy for diabetic retinopathy.

Brand names: Drusen Laz
Other names: combined antioxidant therapy-University of GuadalajaraCombined antioxidant therapy

Targets

H2O2 (Hydrogen peroxide)

Beyond the preview

Go deeper on Drusen Laz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Drusen Laz.

Explore the full profile